Guselkumab becomes first IL-23 inhibitor with FDA-approved label for halting structural joint damage in psoriatic arthritis, backed by Phase...

With 51% of Alzheimer's disease-modifying compounds failing Phase III, The Lancet's case for MAMS platform trials in neurology isn't...

At the 2026 Veeva R&D and Quality Summit in Copenhagen, Veeva Systems announced three major AI capabilities: Vault AI,...

Ribo submits RBD1119 Phase 2 application to EMA for coronary artery disease, targeting residual thrombotic risk in stable CAD...

Zanidatamab doubles survival in HER2-positive gastric cancer trial, achieving 29.7 months median OS versus 15.8 months with trastuzumab in...

TG Therapeutics' ublituximab shows bioequivalent exposure in single-dose trial, potentially simplifying MS treatment initiation with reduced clinic visits.

Zumilokibart achieves EASI-75 target in Phase 2 atopic dermatitis trial with fewer injections than dupilumab and lower conjunctivitis rates.

Kordata Dynamics launches an AI model built for real-time neural data in trials. Here's what it means for site...

Novartis presents eGFR slope data for IgAN kidney disease treatments at ERA 2026, comparing complement inhibition and endothelin receptor...

FDA Approves DECNUPAZ for blastic plasmacytoid dendritic cell neoplasm, achieving 69.7% composite complete response in newly diagnosed patients.